New data from Dexcom has demonstrated the benefit of its G7 continuous glucose monitor (CGM) in type 2 diabetes (TD2) patients not receiving insulin, suggesting a new standard of care (SoC) could be ...

June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...

Designed to provide real-time glucose readings for an industry-leading 15.5 days, Dexcom G7 15 Day will be available in the U.S. for people over the age of 18 with diabetes beginning on Dec. 1, 2025.

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...

Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support. The Apple Watch can make glucose checks quicker, but it does not measure blood ...